|
1
|
Wyatt RJ and Julian BA: IgA Nephropathy. N
Engl J Med. 368:2402–2414. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Shaughnessy MM, Hogan SL, Thompson BD,
Coppo R, Fogo AB and Jennette JC: Glomerular disease frequencies by
race, sex and region: Results from the international kidney biopsy
survey. Nephrol Dial Transplant. Jul 2–2017.(Epub ahead of
print).
|
|
3
|
Moriyama T, Tanaka K, Iwasaki C, Oshima Y,
Ochi A, Kataoka H, Itabashi M, Takei T, Uchida K and Nitta K:
Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at
a single center in Japan. PLoS One. 9:e917562014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rasche FM, Keller F, Rasche WG, Schiekofer
S, Boldt A, Sack U and Fahnert J: Why, when and how should
immunosuppressive therapy considered in patients with
immunoglobulin A nephropathy? Clin Exp Immunol. 186:115–133. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jonsson CA and Carlsten H: Mycophenolic
acid inhibits inosine 5′-monophophate dehydrogenase and suppresses
immunoglobulin and cytokine production of B cells. Int
Immunopharmacol. 3:31–37. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Allison AC and Eugui EM: Mycophenolate
mofetil and its mechanisms of action. Immunopharmacology.
47:85–118. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee SH, Kim CD, Huh KH, Cho BH, Ju MK, Lee
DR, Cho HR, Park JW, Lee JJ, Lee S, et al: Low-dose mycophenolate
mofetil in tablet form or capsule form combined with tacrolimus in
the early period after kidney transplantation: A prospective
randomized trial. Clin Nephrol. 86:319–327. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Glander P, Hambach P, Braun KP, Fritsche
L, Waiser J, Mai I, Neumayer HH and Budde K: Effect of
mycophenolate mofetil on IMP dehydrogenase after the first dose and
after long-term treatment in renal transplant recipients. Int J
Clin Pharmacol Ther. 41:470–476. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hou JH, Le WB, Chen N, Wang WM, Liu ZS,
Liu D, Chen JH, Tian J, Fu P, Hu ZX, et al: Mycophenolate mofetil
combined with prednisone versus full-dose prednisone in IgA
nephropathy with active proliferative lesions: A randomized
controlled trial. Am J Kidney Dis. 69:788–795. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hogg RJ, Bay RC, Jennette JC, Sibley R,
Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, et
al: Randomized controlled trial of mycophenolate mofetil in
children, adolescents, and adults with IgA nephropathy. Am J Kidney
Dis. 66:783–791. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Dewei D, Sun S, Xu G, Liu H, He L
and Zhang P: Treatment of severe IgA nephropathy: Mycophenolate
mofetil/prednisone compared to cyclophosphamide/prednisone. Int J
Clin Pharmacol Ther. 52:95–102. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu XW, Li DM, Xu GS and Sun SR:
Comparison of the therapeutic effects of leflunomide and
mycophenolate mofetil in the treatment of immunoglobulin A
nephropathy manifesting with nephrotic syndrome. Int J Clin
Pharmacol Ther. 48:509–513. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang SC, Tang AW, Wong SS, Leung JC, Ho YW
and Lai KN: Long-term study of mycophenolate mofetil treatment in
IgA nephropathy. Kidney Int. 77:543–549. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang S, Leung JC, Chan LY, Lui YH, Tang
CS, Kan CH, Ho YW and Lai KN: Mycophenolate mofetil alleviates
persistent proteinuria in IgA nephropathy. Kidney Int. 68:802–812.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Frisch G, Lin J, Rosenstock J, Markowitz
G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A and
Appel G: Mycophenolate mofetil (MMF) vs placebo in patients with
moderately advanced IgA nephropathy: A double-blind randomized
controlled trial. Nephrol Dial Transplant. 20:2139–2145. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maes BD, Oyen R, Claes K, Evenepoel P,
Kuypers D, Vanwalleghem J, Van Damme B and Vanrenterghem YF:
Mycophenolate mofetil in IgA nephropathy: Results of a 3-year
prospective placebo-controlled randomized study. Kidney Int.
65:1842–1849. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen X, Chen P, Cai G, Wu J, Cui Y, Zhang
Y, Liu S and Tang L: A randomized control trial of mycophenolate
mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi.
82:796–801. 2002.(In Chinese). PubMed/NCBI
|
|
18
|
Du B, Jia Y, Zhou W, Min X, Miao L and Cui
W: Efficacy and safety of mycophenolate mofetil in patients with
IgA nephropathy: An update meta-analysis. BMC Nephrol. 18:2452017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vecchio M, Bonerba B, Palmer SC, Craig JC,
Ruospo M, Samuels JA, Molony DA, Schena FP and Strippoli GF:
Immunosuppressive agents for treating IgA nephropathy. Cochrane
Database Syst Rev. 2015:CD0039652015.
|
|
20
|
Chen Y, Li Y, Yang S, Li Y and Liang M:
Efficacy and safety of mycophenolate mofetil treatment in IgA
nephropathy: A systematic review. BMC Nephrol. 15:1932014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu G, Tu W, Jiang D and Xu C:
Mycophenolate mofetil treatment for IgA nephropathy: A
meta-analysis. Am J Nephrol. 29:362–367. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Higgins JP and Green S: Cochrane handbook
for systematic reviews of interventions. version 5.1.0. The
Cochrane Collaboration. 2011.http://handbook.cochrane.orgUpdated March
2011.
|
|
23
|
Knobloch K, Yoon U and Vogt PM: Preferred
reporting items for systematic reviews and meta-analyses (PRISMA)
statement and publication bias. J Craniomaxillofac Surg. 39:91–92.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deierhoi MH, Kauffman RS, Hudson SL,
Barber WH, Curtis JJ, Julian BA, Gaston RS, Laskow DA and Diethelm
AG: Experience with mycophenolate mofetil (RS61443) in renal
transplantation at a single center. Ann Surg. 217:476–484. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rovin BH: Lupus nephritis: Guidelines for
lupus nephritis-more recommendations than data? Nat Rev Nephrol.
8:620–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Conti F, Ceccarelli F, Perricone C,
Massaro L, Cipriano E, Pacucci VA, Truglia S, Miranda F, Morello F,
Alessandri C, et al: Mycophenolate mofetil in systemic lupus
erythematosus: Results from a retrospective study in a large
monocentric cohort and review of the literature. Immunol Res.
60:270–276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Langman LJ, LeGatt DF, Halloran PF and
Yatscoff RW: Pharmacodynamic assessment of mycophenolic
acid-induced immunosuppression in renaltransplant recipients.
Transplantation. 62:666–672. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park JS, Kim GH, Jo CH, Kim S, Lee CH, Kim
YS and Kang CM: Effect of mycophenolic acid on cyclosporin
A-induced fibronectin expression in rat mesangial cells.
Pharmacology. 91:20–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dubus I, Vendrely B, Christophe I,
Labouyrie JP, Delmas Y, Bonnet J and Combe C: Mycophenolic acid
antagonizes the activation of cultured human mesangial cells.
Kidney Int. 62:857–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hauser IA, Renders L, Radeke HH, Sterzel
RB and Goppelt-Struebe M: Mycophenolate mofetil inhibits rat and
human mesangial cell proliferation by guanosine depletion. Nephrol
Dial Transplant. 14:58–63. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Al Hussain T, Hussein MH, Al Mana H and
Akhtar M: Pathophysiology of IgA Nephropathy. Adv Anat Pathol.
24:56–62. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lai KN: Pathogenesis of IgA nephropathy.
Nat Rev Nephrol. 8:275–283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Beckwith H, Medjeral-Thomas N, Galliford
J, Griffith M, Levy J, Lightstone L, Palmer A, Roufosse C, Pusey C,
Cook HT and Cairns T: Nephrol Dial Transplant. 32 Suppl
1:i123–i128. 2017. View Article : Google Scholar : PubMed/NCBI
|
